2985 - Hypofractionated Radiotherapy with Concomitant Boost Can be Safely Given in Early Breast Cancer Patients: A Single Institutional Experience
Presenter(s)
M. J. Prasad2, M. J. Prasad2, J. Singh3, M. Prasad4, and S. Kumar4; 1MOHANS MEDICITY HOSPITAL, MADURAI, Tamil Nadu, India, 2Vellamal Medical College, Madurai, India, 3Tirunelveli Medical College, Madurai, India, 4Madurai Medical College, Madurai, India
Purpose/Objective(s): Hypofractionated radiotherapy with concomitant boost for breast cancer is a safe and effective strategy as seen in large prospective trials. This study aimed to assess overall and disease-free survivals, local control, and acute and late toxicities in patients treated with hypofractionated radiotherapy with concomitant boost in early breast cancers.
Materials/Methods: Data from patients submitted treated with hypofractionated radiotherapy with concomitant boost, were evaluated retrospectively. Demographic, disease, and treatment characteristics were collected.
Results: From January 2018 to December 2023, 524 patients of early breast cancer were treated. Breast-conserving surgery was performed in 85 %, immediate reconstruction after mastectomy in 6 (1.1%). Most patients (91.2%) had initial stage (0 to IIA), and chemotherapy was performed in 92%, Hypofractionated radiotherapy was mainly performed in 15 or 16 daily fractions of 267 cGy and 265 cGy, respectively. Concomitant boost dose was 180 cgy five fractions combined during the start of hypofractionated radiotherapy.The median follow-up was 5 years. There were 14 deaths and 2 local recurrences. At 3 years the overall survival was 92%, local control 96%, and disease-free survival was 95% respectively. Only 110 patients completed 5 years period from completion of treatment and the 5 year overall survival was 91%, local control rates were 95% and disease free survival was 93 % respectively. Acute grade 3 or 4 dermatitis was observed in 0.9%. Late grade 1 or 2 occurred in less than 3% of the patients.
Conclusion: Hypofractionated radiotherapy with concomitant boost can be safely given in Early breast cancer patients with an average median survival rate of 95% at 3 years and 91% at 5 years with very low acute and late toxicity.